BMO Capital Maintains Outperform on Amgen, Raises Price Target to $275

BMO Capital maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $240 to $275.

Benzinga · 01/09/2020 16:56

BMO Capital maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $240 to $275.